Belite Bio Inc. ADS/$BLTE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Belite Bio Inc. ADS
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Ticker
$BLTE
Sector
Primary listing
Employees
-
Headquarters
Website
BLTE Metrics
BasicAdvanced
$2.5B
-
-$0.78
-1.50
-
Price and volume
Market cap
$2.5B
Beta
-1.5
52-week high
$79.95
52-week low
$49.00
Average daily volume
53K
Financial strength
Current ratio
23.148
Interest coverage (TTM)
-1,284.10%
Profitability
EBITDA (TTM)
-25.5
Effective tax rate (TTM)
-0.05%
Management effectiveness
Return on assets (TTM)
-11.68%
Return on equity (TTM)
-17.33%
Valuation
Price to book
16.83
Price to tangible book (TTM)
16.83
Growth
Earnings per share change (TTM)
-36.07%
3-year earnings per share growth (CAGR)
4.46%
Bulls say / Bears say
In August 2025, Belite Bio completed a registered direct offering of 230,770 ADSs and warrants at $65 per unit, raising $15 million, and in September 2025 secured $125 million upfront through a PIPE led by RA Capital, highlighting strong investor conviction in its clinical pipeline (Nasdaq) (GlobeNewswire)
The FDA granted Breakthrough Therapy Designation for Tinlarebant in May 2025, adding to its existing Fast Track, Rare Pediatric Disease, Orphan Drug (U.S./EU/Japan), and Pioneer Drug (Japan) designations, expediting its development and regulatory engagement (GlobeNewswire)
Belite Bio’s pivotal Phase 3 PHOENIX trial for geographic atrophy finished enrollment with 529 subjects and its Phase 3 DRAGON trial is proceeding on schedule with completion expected in Q4 2025, de-risking key development milestones (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
BLTE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Belite Bio Inc. ADS stock?
Belite Bio Inc. ADS (BLTE) has a market cap of $2.5B as of October 08, 2025.
What is the P/E ratio for Belite Bio Inc. ADS stock?
The price to earnings (P/E) ratio for Belite Bio Inc. ADS (BLTE) stock is 0 as of October 08, 2025.
Does Belite Bio Inc. ADS stock pay dividends?
No, Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next Belite Bio Inc. ADS dividend payment date?
Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders.
What is the beta indicator for Belite Bio Inc. ADS?
Belite Bio Inc. ADS (BLTE) has a beta rating of -1.5. This means that it has an inverse relation to market volatility.